Gilead Sciences (GILD) Projected to Post Earnings on Tuesday

Gilead Sciences (NASDAQ:GILD) is expected to post its quarterly earnings results after the market closes on Tuesday, February 11th. Analysts expect Gilead Sciences to post earnings of $1.66 per share and revenue of $7.15 billion for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.29 EPS. On average, analysts expect Gilead Sciences to post $4 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Gilead Sciences Stock Performance

Shares of GILD opened at $96.04 on Monday. The firm has a market capitalization of $119.69 billion, a P/E ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $100.51. The stock has a 50 day moving average price of $93.04 and a two-hundred day moving average price of $86.76. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 572,824 shares of company stock valued at $53,611,715. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of a number of research analyst reports. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price target for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Oppenheimer increased their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Finally, Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.